Prosecution Insights
Prosecution Insights
9 pending office actions • 8 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 8 (89%) |
| §102 only | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 36.9% | +15.9% |
| CERIONI, DANIEL LEE | 1 | 64.8% | +28.3% |
| PAULUS, ERIN VIRGINIA | 1 | 37.5% | +83.3% |
| NGUYEN, HUONG Q | 1 | 45.6% | +44.3% |
| HIRAKIS, SOPHIA P | 1 | 41.2% | +74.1% |
| WEBSTER, KARMEL JOHANNA | 1 | 61.1% | +33.3% |
| RAHMAN, MASUDUR | 1 | 70.5% | +32.3% |
| GIBBS, TERRA C | 1 | 64.1% | +10.6% |
| BALLARD, KIMBERLY | 1 | 53.7% | +48.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18449091 | DEVICE, SYSTEM AND METHOD FOR MONITORING NEUROLOGICAL FUNCTIONAL STATUS | CERIONI, DANIEL LEE | 56d overdue |
| 18000011 | NONINVASIVE CRANIAL NERVE THERAPY | WEBSTER, KARMEL JOHANNA | 52d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 29d overdue |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 10d overdue |
| 17782611 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | GIBBS, TERRA C | 10d overdue |
| 17817125 | PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS | RAHMAN, MASUDUR | 9d |
| Art Unit | Apps |
|---|---|
| 3791 | 2 |
| 1628 | 1 |
| 1631 | 1 |
| 1623 | 1 |
| 3792 | 1 |
| 1633 | 1 |
| 1635 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | 10d overdue | Pending | Sep 29, 2023 |
| 18449091 | DEVICE, SYSTEM AND METHOD FOR MONITORING NEUROLOGICAL FUNCTIONAL STATUS | CERIONI, DANIEL LEE | 3791 | §103 | Final Rejection | 56d overdue | Pending | Aug 14, 2023 |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 1631 | §103 | Non-Final OA | 29d overdue | Pending | Mar 31, 2023 |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 3791 | §103 | Final Rejection | 29d overdue | Pending | Mar 28, 2023 |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | 78d overdue | Pending | Jan 17, 2023 |
| 18000011 | NONINVASIVE CRANIAL NERVE THERAPY | WEBSTER, KARMEL JOHANNA | 3792 | §103 | Final Rejection | 52d overdue | Pending | Nov 28, 2022 |
| 17817125 | PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS | RAHMAN, MASUDUR | 1633 | §102 | Final Rejection | 9d | Pending | Aug 03, 2022 |
| 17782611 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | GIBBS, TERRA C | 1635 | §103 | Final Rejection | 10d overdue | Pending | Jun 03, 2022 |
| 17317057 | DETECTION OF AUTOREACTIVE FECAL IMMUNOGLOBULIN A (IGA) FOR DIAGNOSIS OF LUPUS | BALLARD, KIMBERLY | 1675 | §103 | Final Rejection | 34d | Pending | May 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial